Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Michael Cross, PhD, Oliver Frank, PhD, Frank Giles, MDMB, Andreas Hochhaus, MD, Christian T. Dietz, PhD, Martin C. Müller, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2015) 126 (23): 135.

https://doi.org/10.1182/blood.V126.23.135.135

Published: 2015

Journal Articles

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Karoline Schubert, Michael Cross, PhD, Sabine Leiblein, Kathrin Wildenberger, Frank Giles, MDMB, Andreas Hochhaus, MD, Oliver Frank, PhD, Dietger Niederwieser, MD, Thoralf Lange, MD

Blood (2014) 124 (21): 3143.

https://doi.org/10.1182/blood.V124.21.3143.3143

Published: 2014

Journal Articles

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Christian Dietz, PhD, Michael Lauseker, PhD, Benjamin Hanfstein, MD, Philippe Rousselot, MD, Thoralf Lange, MD, Jacqueline Maier, PhD, Letizia Foroni, Gareth Gerrard, Rodica Talmaci, PhD, Jeroen JWM Janssen, MD, Oliver Frank, PhD, Susanne Saussele, MD, Frank Giles, MDMB, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2014) 124 (21): 3144.

https://doi.org/10.1182/blood.V124.21.3144.3144

Published: 2014

Journal Articles

Telomere Shortening At Diagnosis Of Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Is Significantly More Pronounced In Patients With Less-Than-Optimal Versus Optimal Molecular Response (ELN criteria) After 12 Months Of Treatment With Nilotinib

Katrin Wenn, Lena Tomala, Fabian Beier, MD, Stefan Wilop, MD, Lucia Vankann, Christian Hasenbank, Oliver Frank, Claudia Walasek, Andreas Hochhaus, MD, Frank Giles, MD MB, Steffen Koschmieder, Patrick Ziegler, PhD, Tim H. Brümmendorf, MD

Blood (2013) 122 (21): 1471.

https://doi.org/10.1182/blood.V122.21.1471.1471

Published: 2013

Journal Articles

Low Level BCR-ABL Mutations Below the Detection Limit of Current Standard Screening Techniques Occur Predominantly in the CD34+ Progenitor Cell Compartment in Chronic Phase CML Patients At Diagnosis. A Substudy of the ENEST1st Trial

Jacqueline Maier, Karoline Schubert, Michael Cross, PhD, Sabine Leiblein, Kathrin Wildenberger, Frank Giles, MD, Andreas Hochhaus, MD, Oliver Frank, Dietger Niederwieser, Thoralf Lange

Blood (2012) 120 (21): 1671.

https://doi.org/10.1182/blood.V120.21.1671.1671

Published: 2012

Journal Articles

Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib.

Alice Fabarius, PhD, Michelle Giehl, Alwin Kraemer, MD, Oliver Frank, PhD, Martin C. Mueller, MD, Peter Duesberg, PhD, Tanja Lahaye, MD, Claudia Schoch, MD, Rudiger Hehlmann, MD, Wolfgang Seifarth, PhD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 2167.

https://doi.org/10.1182/blood.V108.11.2167.2167

Published: 2006

Journal Articles

Dynamics of Cytogenetic Aberrations in Philadelphia Chromosome Positive and Negative Hematopoiesis during Dasatinib Therapy of Chronic Myeloid Leukemia Patients after Imatinib Failure.

Alice Fabarius, PhD, Claudia Schoch, MD, Martin C. Mueller, MD, Philipp Erben, MD, Tanja Lahaye, MD, Michelle Giehl, Oliver Frank, PhD, Wolfgang Seifarth, PhD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 2114.

https://doi.org/10.1182/blood.V108.11.2114.2114

Published: 2006

Journal Articles

Tumor cells escape suicide gene therapy by genetic and epigenetic instability

Oliver Frank, Cornelia Rudolph, Christoph Heberlein, Nils von Neuhoff, Evelin Schröck, Axel Schambach, Brigitte Schlegelberger, Boris Fehse, Wolfram Ostertag, Carol Stocking, Christopher Baum

Blood (2004) 104 (12): 3543–3549.

https://doi.org/10.1182/blood-2004-03-0852

Published: 2004

Journal Articles

Centrosome Aberrations in Chronic Myeloid Leukemia (CML) Are Correlated with Disease Progression and Chromosome Instability.

Michelle Giehl, Alice Fabarius, Chun Zheng, Oliver Frank, Andreas Hochhaus, Mathias Hafner, Rudiger Hehlmann, Wolfgang Seifarth

Blood (2004) 104 (11): 2949.

https://doi.org/10.1182/blood.V104.11.2949.2949

Published: 2004

NARROW

Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial

Low Level BCR-ABL Mutations and Response to Treatment: A Substudy of the ENEST1st Trial

Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study

Telomere Shortening At Diagnosis Of Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Is Significantly More Pronounced In Patients With Less-Than-Optimal Versus Optimal Molecular Response (ELN criteria) After 12 Months Of Treatment With Nilotinib

Low Level BCR-ABL Mutations Below the Detection Limit of Current Standard Screening Techniques Occur Predominantly in the CD34+ Progenitor Cell Compartment in Chronic Phase CML Patients At Diagnosis. A Substudy of the ENEST1st Trial

Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib.

Dynamics of Cytogenetic Aberrations in Philadelphia Chromosome Positive and Negative Hematopoiesis during Dasatinib Therapy of Chronic Myeloid Leukemia Patients after Imatinib Failure.

Tumor cells escape suicide gene therapy by genetic and epigenetic instability

Centrosome Aberrations in Chronic Myeloid Leukemia (CML) Are Correlated with Disease Progression and Chromosome Instability.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only